킵스파마
Financials
Valuation Metrics
킵스파마's Market Cap is ₩1215B. At end of 2025 it was ₩2088B. Ranked #1164 of 2,421 in KR market (top 48%), #618 of 1,640 on KOSDAQ (top 38%), #126 of 214 in Semiconductors & Semiconductor Equipment (top 59%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 121.47B KRW | KR#1,164/2,421 Sec#126/214 |
| Revenue | 220.48B KRW | KR#974/2,421 Sec#68/214 |
| Net Income | -13.02B KRW | KR—/2,421 Sec—/214 |
| Total Assets | 233.88B KRW | KR#1,198/2,421 Sec#98/214 |
| Net Assets | 79.65B KRW | KR#1,590/2,421 Sec#139/214 |
| Employees | 27 | KR#2,217/2,421 Sec#204/214 |
| Value | ||
| P/B | 1.53x | KR#1,780/2,421 Sec#105/214 |
| P/S | 0.55x | KR#989/2,421 Sec#37/214 |
| FCF Yield | -38.57% | KR—/2,421 Sec—/214 |
| Profitability | ||
| ROE | -16.34% | KR#2,048/2,421 Sec#180/214 |
| ROA | -5.56% | KR#1,958/2,421 Sec#168/214 |
| Op. Margin | -0.27% | KR#1,627/2,421 Sec#137/214 |
| Revenue Growth | 48.61% | KR#215/2,421 Sec#36/214 |
| Financial Health | ||
| Debt Ratio | 193.65% | KR#2,086/2,421 Sec#194/214 |
| Total Debt | 94.56B KRW | KR#751/2,421 Sec#43/214 |
| FCF | -46.85B KRW | KR#2,073/2,421 Sec#191/214 |
| Cash | 11.54B KRW | KR#1,614/2,421 Sec#151/214 |
| Current Ratio | 1.06x | KR#1,650/2,421 Sec#157/214 |
| Performance | ||
| 1Y Return | -46.41% | KR#1,978/2,421 Sec#196/214 |
| 1M Return | 7.27% | KR#615/2,421 Sec#86/214 |
| From 52W High | -53.03% | KR#1,545/2,421 Sec#138/214 |
| 1Y MDD | -57.27% | KR#1,326/2,421 Sec#74/214 |
| Trading | ||
| Volume | 22,867 shares | KR#1,519/2,421 Sec#172/214 |
| Trading Value | 137.1M KRW | KR#1,421/2,421 Sec#168/214 |
| Foreign Own. | 2.67% | KR#1,402/2,421 Sec#149/214 |
| Per Share | ||
| EPS | -648 KRW | KR—/2,421 Sec—/214 |
| BPS | 3,967 KRW | KR#1,677/2,421 Sec#150/214 |
Company Info
KeepsPharma, established in 2000 and headquartered in Hwaseong-si, Gyeonggi-do, transitioned to the pharmaceutical and biotechnology sector in 2025, following its KOSDAQ listing in 2017. The company's primary activities include the manufacturing and sales of specialized medicines, development of oral peptide drug delivery platforms, anticancer treatments, and medical devices. KeepsPharma is also diversifying its business through the expansion of CDMO and CMO services, LFP recycling, and the localization of micro OLED equipment and fine metal masks.